IGKV1D-22 and colonic neoplasm: Simultaneously, ITGA9 is obviously up-regulated in already-developed drug-resistant colon cancer cells, whereas α9 is reported to be a promising target candidate for overcoming methotrexate resistance in colon cancer (95).